Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$15.80
-1.9%
$18.97
$15.66
$35.84
$456.18M1.19405,766 shs530,958 shs
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$4.15
+2.2%
$5.92
$3.99
$28.41
$375.58M2.151.79 million shs2.75 million shs
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
$10.75
-0.3%
$10.76
$10.20
$11.30
$156.52M-0.01121,140 shs3,300 shs
Personalis, Inc. stock logo
PSNL
Personalis
$4.69
-1.9%
$3.92
$1.14
$7.20
$414.24M1.831.01 million shs528,764 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-1.86%-4.24%-23.41%-39.04%-35.17%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
+2.22%-11.51%-29.90%-72.48%-83.76%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.00%0.00%0.00%0.00%0.00%
Personalis, Inc. stock logo
PSNL
Personalis
-1.88%-5.44%+22.14%+4.69%+250.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.1676 of 5 stars
4.52.00.00.03.52.50.0
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
3.4288 of 5 stars
3.92.00.00.02.90.82.5
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
4.3615 of 5 stars
3.54.00.04.22.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$37.00134.18% Upside
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
1.86
Reduce$15.00261.45% Upside
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.00
N/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
3.00
Buy$7.6763.47% Upside

Current Analyst Ratings Breakdown

Latest HHLA, CSTL, PSNL, and FTRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/21/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.00
5/15/2025
Personalis, Inc. stock logo
PSNL
Personalis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.00
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.00
5/13/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.00
5/7/2025
Personalis, Inc. stock logo
PSNL
Personalis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $35.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $37.00
5/2/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$7.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$347.08M1.31N/AN/A$14.54 per share1.09
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$2.69B0.14$0.66 per share6.28$19.58 per share0.21
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/A$1.71 per share6.29($1.19) per shareN/A
Personalis, Inc. stock logo
PSNL
Personalis
$85.69M4.83N/AN/A$2.64 per share1.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$57.47M-$0.1979.00N/AN/A1.95%1.47%1.27%8/4/2025 (Estimated)
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$3.40M-$8.79N/A3.241.78-10.99%2.00%0.80%8/11/2025 (Estimated)
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
$17.69M-$0.14N/AN/AN/A-57.47%-0.35%N/A
Personalis, Inc. stock logo
PSNL
Personalis
-$108.30M-$1.29N/AN/AN/A-104.52%-66.07%-41.34%8/6/2025 (Estimated)

Latest HHLA, CSTL, PSNL, and FTRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million
5/6/2025Q1 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million
5/5/2025Q1 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million
3/3/2025Q4 2024
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$0.36$0.18-$0.18-$0.68$703.22 million$697.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/AN/AN/AN/AN/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
7.78
7.64
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
0.74
1.18
1.18
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/A
0.03
0.03
Personalis, Inc. stock logo
PSNL
Personalis
N/A
4.68
4.44

Institutional Ownership

CompanyInstitutional Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/A
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
39.24%
Personalis, Inc. stock logo
PSNL
Personalis
61.91%

Insider Ownership

CompanyInsider Ownership
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
6.50%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
0.12%
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
0.54%
Personalis, Inc. stock logo
PSNL
Personalis
3.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54028.87 million25.99 millionOptionable
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
18,00090.50 million89.59 millionOptionable
HH&L Acquisition Co. stock logo
HHLA
HH&L Acquisition
N/A14.56 million14.48 millionNot Optionable
Personalis, Inc. stock logo
PSNL
Personalis
40088.33 million67.75 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$15.80 -0.30 (-1.86%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$16.34 +0.54 (+3.44%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Fortrea stock logo

Fortrea NASDAQ:FTRE

$4.15 +0.09 (+2.22%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.27 +0.12 (+2.89%)
As of 07:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

HH&L Acquisition stock logo

HH&L Acquisition NYSE:HHLA

HH&L Acquisition Co. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on healthcare or healthcare-related companies in Asian markets. HH&L Acquisition Co. was incorporated in 2020 and is based in Central, Hong Kong.

Personalis stock logo

Personalis NASDAQ:PSNL

$4.69 -0.09 (-1.88%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.70 +0.00 (+0.11%)
As of 06:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.